Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Canada
  5. Blackhawk Growth Corp.
  6. News
  7. Summary
    BLR   CA09238B3083


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Blackhawk Growth : MindBio Therapeutics Brings Digital Mental Health Technology To Psychedelics Clinical Trials

10/07/2021 | 06:01am EST

(via TheNewswire)


Vancouver, British Columbia -TheNewswireOctober 7, 2021Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that MindBio Therapeutics is developing a mental health technology platform to integrate with psychedelic treatments in clinical trials in patients suffering pain who are susceptible to depression, existential distress and anxiety.

MindBio, a 100% owned subsidiary of Blackhawk, through its recent collaboration agreement with Digital Mind Technology, has begun to develop solutions to prevent deteriorating mental health. Cancer patients suffering pain will be able to access these solutions through their mobile devices, desktops and wearables.

Pain, endured unsustainably can lead to depression and anxiety. The foundational research and product development being progressed by MindBio, in its collaboration with Digital Mind Technology, is about creating new digital models to intervene in pain management experienced in cancer patients. The aim is to create interventions using technology to prevent negative mental health outcomes and apply these learnings to diverse patient cohorts.

MindBio Therapeutics aims to commercialize the intellectual property globally. As recently seen in Europe, some of these digital and web applications have the potential to reach reimbursement status, where therapeutic bodies and governments provide funding for the use of these digital therapeutics by doctor’s prescription. The first prescription digital health applications were approved for reimbursement in Germany in September 2020 by the Federal Institute for Drugs and Medical Devices. Since then, many web applications have been reimbursed for use in a wide range of conditions including tinnitus, insomnia, anxiety, pain, obesity, migraine, and multiple sclerosis1.

Concurrently, MindBio Therapeutics through its psychedelics microdosing program at the University of Auckland in New Zealand, has had Phase 2 clinical trials microdosing LSD in late-stage cancer patients approved by the New Zealand government who have committed NZ$250,000 in funding to support this important efficacy work.  In these trials, a small group of late-stage cancer patients will be trialled on a drug only vs a drug and mindfulness therapy and if successful will lead to a much larger phase 2 clinical trial.

MindBio is actively partnering and looking for acquisitions in technology solutions, clinics and treatments that fit strategically alongside its clinical trial drug development research activities.

“We are very pleased to be pioneering this collaboration and leading a multi-disciplinary framework in the psychedelics and mental health treatments ecosystem” says FrederickPels, CEO of Blackhawk Growth Corp. “This important work in mental wellness technology, digital therapies and psychedelics clinical research in oncology is paving the way for novel and emerging treatments to change the way mental health treatments are provided around the world.

About Blackhawk Growth


Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics.Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channelhttps://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group athttps://t.me/Blackhawkgrowthcorpand visit us online athttps://www.blackhawkgrowth.com.

  1. 1.https://www.pharmaceutical-technology.com/comment/digital-therapeutics-germany 

For further information please contact:

Frederick Pels, Chief Executive Officer



Cautionary Note Regarding Forward-Looking Statement


All statements in this press release, other thanstatements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be otherfactors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2021 TheNewswire - All rights reserved.

Copyright (c) 2021 TheNewswire - All rights reserved., source Press Releases

12/01Blackhawk Growth Completes Investment in California-Based Licensed Distribution Center ..
11/29Blackhawk Growth Files Quarter Ended September 30, 2021 Financials and Reports Increase..
11/29Blackhawk Growth Corp. Reports Earnings Results for the First Quarter Ended September 3..
11/23Blackhawk Growth Corp. Announces Financing Agreement
11/23Blackhawk Growth Enters into Credit Facility for up to $10 Million
11/23Blackhawk Growth Corp. announced that it expects to receive CAD 10 million in funding
11/15Blackhawk growth's mindbio therapeutics advances microdosing clinical trial to 59 patie..
11/15Blackhawk Growth's MindBio Therapeutics Advances Microdosing Clinical Trial to 59 Patie..
11/08Blackhawk growth's mindbio therapeutics completes safety milestone in its phase 1 clini..
11/08Blackhawk Growth's MindBio Therapeutics Completes Safety Milestone in its Phase 1 Clini..
More news
Sales 2021 0,83 M 0,65 M 0,65 M
Net income 2021 -2,52 M -1,96 M -1,96 M
Net cash 2021 0,68 M 0,53 M 0,53 M
P/E ratio 2021 -3,33x
Yield 2021 -
Capitalization 32,5 M 25,4 M 25,3 M
EV / Sales 2020 -15,0x
EV / Sales 2021 13,7x
Nbr of Employees -
Free-Float 97,8%
Duration : Period :
Blackhawk Growth Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Frederick Pels President, Chief Executive Officer & Director
David M. Antony Chairman
Dale S. Owen Independent Director
Alexander Klenman Director
Marc Lowenstein Director
Sector and Competitors
1st jan.Capi. (M$)
BLACKSTONE INC.117.93%100 934
KKR & CO. INC.86.42%44 156
LEGAL & GENERAL PLC7.40%22 394
AMUNDI9.81%16 791